EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib

Jung Woo Eun, Jung Hwan Yoon iD, Hye Ri Ahn, Seokhwi Kim, Young Bae Kim, Su Bin Lim, Won Park, Tae Wook Kang, Geum Ok Baek, Moon Gyeong Yoon, Ju A Son, Ji Hyang Weon und 3 weitere

Cancer Communications · 2023-04 · 43 (4) · 455-479

DOI: 10.1002/cac2.12414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 14.03.2023. Verfasst von Jung Woo Eun und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ajou University School of Medicine, Suwon, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Cancer-Associated Fibroblasts, Liver Neoplasms. Die Arbeit wurde bisher 207-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health and Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer‐associated fibroblasts (CAFs) play an important role in the induction of chemo‐resistance. This study aimed to clarify the mechanism underlying CAF‐mediated resistance to two tyrosine kinase inhibitors (TKIs), sorafenib and lenvatinib, and to identify a novel therapeutic target for overcoming TKI resistance in hepatocellular carcinoma (HCC).

Methods

We performed a systematic integrative analysis of publicly available gene expression datasets and whole‐transcriptome sequencing data from 9 pairs of CAFs and para‐cancer fibroblasts isolated from human HCC and para‐tumor tissues, respectively, to identify key molecules that might induce resistance to TKIs. We then performed in vitro and in vivo experiments to validate selected targets and related mechanisms. The associations of plasma secreted phosphoprotein 1 (SPP1) expression levels before sorafenib/lenvatinib treatment with progression‐free survival (PFS) and overall survival (OS) of 54 patients with advanced HCC were evaluated using Kaplan‐Meier and Cox regression analysis.

Results

Bioinformatic analysis identified CAF‐derived SPP1 as a candidate molecule driving TKI resistance. SPP1 inhibitors reversed CAF‐induced TKI resistance in vitro and in vivo. CAF‐derived SPP1 activated rapidly accelerated fibrosarcoma (RAF)/mitogen‐activated protein kinase (MAPK) and phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) through the integrin‐protein kinase C‐alpha (PKCα) signaling pathway and promoted epithelial‐to‐mesenchymal transition (EMT). A high plasma SPP1 level before TKI treatment was identified as an independent predictor of poor PFS ( P = 0.026) and OS ( P = 0.047) in patients with advanced HCC after TKI treatment.

Conclusions

CAF‐derived SPP1 enhances TKI resistance in HCC via bypass activation of oncogenic signals and EMT promotion. Its inhibition represents a promising therapeutic strategy against TKI resistance in HCC. Moreover, plasma SPP1 level before TKI treatment represents a potential biomarker for treatment response prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularCancer-Associated FibroblastsLiver NeoplasmsHumansSorafenibPhosphatidylinositol 3-KinasesOsteopontinPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

drug resistanceepithelial-to-mesenchymal transitionhepatocellular carcinomasecreted phosphoprotein 1

Substanzen

SorafenibPhosphatidylinositol 3-KinasesOsteopontinlenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Gastroenterology, Ajou University School of Medicine, Suwon, South Korea.
  • Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea.
  • Department of Pathology, Ajou University School of Medicine, Suwon, South Korea.
  • Department of Biochemistry & Molecular Biology, Ajou University School of Medicine, Suwon, South Korea.
  • The Moagen, Inc, Daejeon, South Korea.

ORCID-Profile: Jung Hwan Yoon, Hyo Jung Cho

Förderung

  • Ministry of Health and Welfare, Republic of Korea

Zitieren

APA

Eun, J. W., Yoon, J. H., Ahn, H. R., Kim, S., Kim, Y. B., Lim, S. B., Park, W., Kang, T. W., Baek, G. O., Yoon, M. G., Son, J. A., Weon, J. H., Kim, S. S., Cho, H. J., & Cheong, J. Y. (2023). Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Communications, 43(4), 455-479. https://doi.org/10.1002/cac2.12414

Vancouver

Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB, et al. Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Communications. 2023;43(4):455-479. doi:10.1002/cac2.12414

BibTeX
@article{Eun2023,
  author = {Eun, Jung Woo and Yoon, Jung Hwan and Ahn, Hye Ri and Kim, Seokhwi and Kim, Young Bae and Lim, Su Bin and Park, Won and Kang, Tae Wook and Baek, Geum Ok and Yoon, Moon Gyeong and Son, Ju A and Weon, Ji Hyang and Kim, Soon Sun and Cho, Hyo Jung and Cheong, Jae Youn},
  title = {Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib},
  journal = {Cancer Communications},
  year = {2023},
  volume = {43},
  number = {4},
  pages = {455--479},
  doi = {10.1002/cac2.12414}
}
Kostenlos starten →